Official Title
Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
Brief Summary

Prevention of COVID-19 infection to severe pneumonea or ARDS

Status
Completed
Conditions
COVID-19
Interventions

Drug: EC-18

EC-18 QD

Drug: Placebo EC-18

Placebo EC-18 QD

Eligibility Criteria

Inclusion Criteria:

- Signed informed consent

- Male or female age 19 years or older

- Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia

Exclusion Criteria:

- Pathologically confirmed diagnosis of bacterial pneumonia or viral pneumonia

- Pregnant or nursing at the time of signing informed consent

- Known sensitivity to any study medication

- Unwilling or unable to complete study diary

- Any other condition or prior therapy that, in the opinion of the Investigator, would
make the subject unsuitable for the study or unable to comply with the protocol

Eligibility Gender
All
Eligibility Age
Minimum: 19 Years ~ Maximum: N/A
Countries
Korea, Republic of
Locations

Chungbuk National University Hospital
Cheongju-si, Korea, Republic of

Investigators

Hyewon Jeong, Principal Investigator
Chungbuk National University Hospital

Sponsors / Collaborators
Enzychem Lifesciences Corporation
NCT Number
NCT04500132
MeSH Terms
COVID-19
Pneumonia